LOXL2 and neoplasm: Prior research demonstrated that LOXL2 released by tumours induced ECM remodelling, leading to heightened stromal stiffness, and stimulated surrounding CAFs via integrin‐mediated focal adhesion kinase (FAK) activation [52] or extracellular signal‐regulated kinase (ERK) activation [53].